Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1313 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3094 | 0.3094 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1313 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3094 | 0.3094 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.6742 | 0.7656 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.1313 | 0.1313 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.1313 | 0.1313 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3094 | 0.3094 |
Brugia malayi | hypothetical protein | 0.0043 | 0.1313 | 0.1491 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1313 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3094 | 0.3094 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.1313 | 0.1313 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.1313 | 0.1313 |
Brugia malayi | hypothetical protein | 0.0182 | 0.8806 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3094 | 0.3514 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.6742 | 0.7656 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.6742 | 0.7656 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3094 | 0.3514 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3094 | 0.3514 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1313 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3094 | 0.3514 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3094 | 0.3514 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3094 | 0.3094 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3094 | 0.3094 |
Onchocerca volvulus | 0.0182 | 0.8806 | 0.5 | |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3094 | 0.3514 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.8806 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3094 | 0.3094 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.122 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.1582 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.632 uM | PUBCHEM_BIOASSAY: qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540272] | ChEMBL. | No reference |
Potency (functional) | 1.9953 uM | PubChem BioAssay. qHTS for Inhibitors of Vif-A3G Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.0596 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.6626 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.4668 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 4.6451 uM | PUBCHEM_BIOASSAY: qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540272] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 29.9349 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504856] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Giardia lamblia |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.